Country
Full text data for US,EP,CN
Type
Legal Validity
Legal Status
Filing Date
Publication Date
Inventor
Assignee
Click to expand
IPC(Section)
IPC(Class)
IPC(Subclass)
IPC(Group)
IPC(Subgroup)
Agent
Agency
Claims Number
Figures Number
Citation Number of Times
Assignee Number
No. Publication Number Title Publication/Patent Number Publication/Patent Number Publication Date Publication Date
Application Number Application Number Filing Date Filing Date
Inventor Inventor Assignee Assignee IPC IPC
1 US10640498B2
Compounds
Publication/Patent Number: US10640498B2 Publication Date: 2020-05-05 Application Number: 16/070,936 Filing Date: 2017-02-16 Inventor: Gibson, Karl Richard   Jones, Alison   Kemp, Mark Ian   Madin, Andrew   Stockley, Martin Lee   Whitlock, Gavin Alistair   Woodrow, Michael D.   Assignee: MISSION THERAPEUTICS LIMITED   IPC: C07D417/12 Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer. The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 ...More ...Less
2 EP3197883B1
NOVEL COMPOUNDS
Publication/Patent Number: EP3197883B1 Publication Date: 2020-03-18 Application Number: 15774652.0 Filing Date: 2015-09-22 Inventor: Jones, Alison   Kemp, Mark Ian   Stockley, Martin Lee   Gibson, Karl Richard   Whitlock, Gavin Alistair   Madin, Andrew   Assignee: Mission Therapeutics Limited   IPC: C07D403/12
3 US10392380B2
Compounds
Publication/Patent Number: US10392380B2 Publication Date: 2019-08-27 Application Number: 15/894,025 Filing Date: 2018-02-12 Inventor: Jones, Alison   Kemp, Mark Ian   Stockley, Martin Lee   Gibson, Karl   Whitlock, Gavin Alistair   Madin, Andrew   Assignee: MISSION THERAPEUTICS LIMITED   IPC: C07D401/12 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB ...More ...Less
4 US2019055232A1
NOVEL COMPOUNDS
Publication/Patent Number: US2019055232A1 Publication Date: 2019-02-21 Application Number: 16/070,936 Filing Date: 2017-02-16 Inventor: Gibson, Karl Richard   Jones, Alison   Kemp, Mark Ian   Madin, Andrew   Stockley, Martin Lee   Whitlock, Gavin Alistair   Woodrow, Michael D.   Assignee: MISSION THERAPEUTICS LIMITED   IPC: C07D417/12 Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 (USP30). The invention further relates to the use of DUB inhibitors in the treatment of conditions involving mitochondrial dysfunction and in the treatment of cancer. The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 30 or ubiquitin specific peptidase 30 ...More ...Less
5 US2019330202A1
NOVEL COMPOUNDS
Publication/Patent Number: US2019330202A1 Publication Date: 2019-10-31 Application Number: 16/448,066 Filing Date: 2019-06-21 Inventor: Jones, Alison   Kemp, Mark Ian   Stockley, Martin Lee   Gibson, Karl Richard   Whitlock, Gavin Alistair   Madin, Andrew   Assignee: MISSION THERAPEUTICS LTD   IPC: C07D417/12 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB ...More ...Less
6 US2019010122A1
2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER
Publication/Patent Number: US2019010122A1 Publication Date: 2019-01-10 Application Number: 16/080,506 Filing Date: 2017-03-17 Inventor: Gibson, Karl Richard   Jones, Alison   Kemp, Mark Ian   Madin, Andrew   Stockley, Martin Lee   Whitlock, Gavin Alistair   Woodrow, Michael D   Menear, Keith Allan   Assignee: MISSION THERAPEUTICS LIMITED   IPC: C07D209/44 Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer. The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The ...More ...Less
7 EP3429994A1
2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER
Publication/Patent Number: EP3429994A1 Publication Date: 2019-01-23 Application Number: 17713408.7 Filing Date: 2017-03-17 Inventor: Gibson, Karl Richard   Jones, Alison   Kemp, Mark Ian   Madin, Andrew   Stockley, Martin Lee   Whitlock, Gavin Alistair   Woodrow, Michael D   Menear, Keith Allan   Assignee: Mission Therapeutics Limited   IPC: C07D209/44
8 US9926307B2
Compounds
Publication/Patent Number: US9926307B2 Publication Date: 2018-03-27 Application Number: 15/513,125 Filing Date: 2015-09-22 Inventor: Jones, Alison   Kemp, Mark Ian   Stockley, Martin Lee   Gibson, Karl Richard   Whitlock, Gavin Alistair   Madin, Andrew   Assignee: MISSION THERAPEUTICS LTD   IPC: C07D513/04 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB ...More ...Less
9 US2018162852A1
NOVEL COMPOUNDS
Publication/Patent Number: US2018162852A1 Publication Date: 2018-06-14 Application Number: 15/894,025 Filing Date: 2018-02-12 Inventor: Madin, Andrew   Whitlock, Gavin Alistair   Gibson, Karl   Stockley, Martin Lee   Kemp, Mark Ian   Jones, Alison   Assignee: Mission Therapeutics Limited   IPC: C07D401/14 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB ...More ...Less
10 EP3416960A1
NOVEL COMPOUNDS
Publication/Patent Number: EP3416960A1 Publication Date: 2018-12-26 Application Number: 17706864.0 Filing Date: 2017-02-16 Inventor: Gibson, Karl Richard   Jones, Alison   Kemp, Mark Ian   Madin, Andrew   Stockley, Martin Lee   Whitlock, Gavin Alistair   Woodrow, Michael D.   Assignee: Mission Therapeutics Limited   IPC: C07D401/14
11 EP3197883A1
NOVEL COMPOUNDS
Publication/Patent Number: EP3197883A1 Publication Date: 2017-08-02 Application Number: 15774652.0 Filing Date: 2015-09-22 Inventor: Madin, Andrew   Whitlock, Gavin Alistair   Jones, Alison   Gibson, Karl Richard   Kemp, Mark Ian   Stockley, Martin Lee   Assignee: Mission Therapeutics Limited   IPC: C07D417/14
12 US2017247365A1
NOVEL COMPOUNDS
Publication/Patent Number: US2017247365A1 Publication Date: 2017-08-31 Application Number: 15/513,125 Filing Date: 2015-09-22 Inventor: Jones, Alison   Kemp, Mark Ian   Stockley, Martin Lee   Gibson, Karl Richard   Whitlock, Gavin Alistair   Madin, Andrew   Assignee: MISSION THERAPEUTICS LTD   Mission therapeutics ltd   IPC: C07D417/12 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB inhibitors in the treatment of cancer and other indications. Compounds of the invention include compounds having the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 to R8 are as defined herein. The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase L1 (UCHL1). The invention further relates to the use of DUB ...More ...Less
13 SG11201700847YA
NOVEL COMPOUNDS
Publication/Patent Number: SG11201700847YA Publication Date: 2017-04-27 Application Number: 11201700847Y Filing Date: 2015-09-22 Inventor: Kemp, Mark Ian   Madin, Andrew   Jones, Alison   Stockley, Martin Lee   Whitlock, Gavin Alistair   Gibson, Karl Richard   Assignee: MISSION THERAPEUTICS LTD   IPC: C07D401/12
14 BR112017005887A2
novos compostos
Title (English): 1
Publication/Patent Number: BR112017005887A2 Publication Date: 2017-12-12 Application Number: 112017005887 Filing Date: 2015-09-22 Inventor: Whitlock, Gavin Alistair   Madin, Andrew   Kemp, Mark Ian   Gibson, Karl Richard   Alison, Jones   Martin, Lee Stockley   Assignee: MISSION THERAPEUTICS LTD   IPC: C07D417/14 Abstract: resumo ?novos compostos? a presente invenção refere-se a novos compostos e métodos para a produção de inibidores de enzimas deubiquilantes (dubs). em particular, a invenção refere-se à inibição da hidrolase c-terminal l1 de ubiquitina (uchl1). a invenção refere-se ainda à utilização de inibidores de dub no tratamento do câncer e outras indicações. os compostos da invenção incluem os compostos com a fórmula (i) (i) ou um sal farmaceuticamente aceitável dos mesmos, em que r1 a r8 são conforme aqui definidos. resumo ?novos compostos? a presente invenção refere-se a novos compostos e métodos para a produção de inibidores de enzimas deubiquilantes (dubs). em particular, a invenção refere-se à inibição da hidrolase c-terminal l1 de ubiquitina (uchl1). a invenção refere-se ainda à uti ...More ...Less
15 WO2017158388A1
2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER
Publication/Patent Number: WO2017158388A1 Publication Date: 2017-09-21 Application Number: 2017050763 Filing Date: 2017-03-17 Inventor: Madin, Andrew   Whitlock, Gavin Alistair   Gibson, Karl Richard   Kemp, Mark Ian   Stockley, Martin Lee   Jones, Alison   Woodrow, Michael D   Assignee: MISSION THERAPEUTICS LIMITED   IPC: A61K31/4035 Abstract: The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular
16 KR20170055499A
NOVEL COMPOUNDS
Publication/Patent Number: KR20170055499A Publication Date: 2017-05-19 Application Number: 20177009125 Filing Date: 2015-09-22 Inventor: Whitlock, Gavin Alistair   Kemp, Mark Ian   Madin, Andrew   Gibson, Karl Richard   Stockley, Martin Lee   Jones, Alison   Assignee: MISSION THERAPEUTICS LTD.   IPC: A61K31/427 Abstract: 본 발명은 신규한 화합물 및 탈 유도체화 효소(deubiquitylating
17 WO2017141036A1
NOVEL COMPOUNDS
Publication/Patent Number: WO2017141036A1 Publication Date: 2017-08-24 Application Number: 2017050403 Filing Date: 2017-02-16 Inventor: Madin, Andrew   Whitlock, Gavin Alistair   Gibson, Karl Richard   Kemp, Mark Ian   Stockley, Martin Lee   Jones, Alison   Woodrow, Michael D   Assignee: MISSION THERAPEUTICS LIMITED   IPC: A61K31/4025 Abstract: The present invention relates to novel compounds of formula (I) and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular
18 AU2015323572A1
Novel compounds
Publication/Patent Number: AU2015323572A1 Publication Date: 2017-03-23 Application Number: 2015323572 Filing Date: 2015-09-22 Inventor: Kemp, Mark Ian   Jones, Alison   Madin, Andrew   Whitlock, Gavin Alistair   Stockley, Martin Lee   Gibson, Karl Richard   Assignee: Mission Therapeutics Ltd   IPC: C07D401/12 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular
19 MX2017003358A
NOVEL COMPOUNDS.
Publication/Patent Number: MX2017003358A Publication Date: 2017-09-13 Application Number: 2017003358 Filing Date: 2015-09-22 Inventor: Madin, Andrew   Whitlock, Gavin Alistair   Gibson, Karl Richard   Jones, Alison   Stockley, Martin Lee   Kemp, Mark Ian   Assignee: MISSION THERAPEUTICS LTD   IPC: C07D401/12 Abstract: The present invention relates to novel compounds and methods for the manufacture of inhibitors of deubiquitylating enzymes (DUBs). In particular
20 GB2537363A
Protector
Publication/Patent Number: GB2537363A Publication Date: 2016-10-19 Application Number: 201506166 Filing Date: 2015-04-12 Inventor: Ian, Karl Jones   Assignee: Pulse Plastics Ltd   IPC: B65D85/04 Abstract: A coil guard 20 has one part 32 to engage a radially outward facing surface 18 of an annular coil 10 and another part 22 to engage a radially inward facing surface 16 of the annular coil 10. Ideally both parts also engage the axially facing surface of the coil. The parts can be releasably fastened together by cooperating hook and loop pads 29 A coil guard 20 has one part 32 to engage a radially outward facing surface 18 of an annular coil 10 and another part 22 to engage a radially inward facing surface 16 of the annular coil 10. Ideally both parts also engage the axially facing surface of the coil. The parts can be ...More ...Less